Ebselen not checked
Sound Pharmaceuticals, Incorporated · SPI-1005
FollowEvery change as it happens, and a Monday email
Trials
3 active
11 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Meniere's Disease, Ménière's Disease, Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection, Hearing Loss, Cochlear Trauma
- Main trialPhase 3
- “Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.”In the company’s words, NCT06859788 on ClinicalTrials.gov
- Other names
- SPI-1005 · Low Dose
Other drugs for Covid19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up2
- DecPhase 3 trial completes · ClinicalTrials.gov
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | SPI-1005 for the Treatment of Meniere's Disease (Open Label) | |
| Phase 2Enrolling by invitation | 31 Dec 2023 | SPI-1005 Treatment in Moderate COVID-19 Patients | |
| Phase 2Recruiting | Dec 2026 | SPI-1005 in Adults Receiving Cochlear Implant | |
| Phase 3Completed | 19 Sep 2023 | SPI-1005 for the Treatment of Meniere's Disease | |
| Phase 2Completed | Dec 2013 | Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift | |
| Phase 2Completed | 30 Apr 2019 | SPI-1005 for the Treatment of Patients With Meniere's Disease | |
| Phase 2Completed | 7 Apr 2023 | SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity | |
| Phase 2Completed | 5 May 2023 | SPI-1005 Treatment in Severe COVID-19 Patients | |
| Phase 2Withdrawn | Jun 2026 | SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | |
| Phase 2Withdrawn | Jun 2026 | A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss | |
| Phase 1/2Completed | Aug 2017 | Study to Evaluate SPI-1005 in Adults With Meniere's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026